Related Experiment Video
Updated: Nov 6, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.8K
[Strategy with Immune Checkpoint Inhibitors for ES‒SCLC]
Shigeru Tanzawa1, Nobuhiko Seki
1Division of Medical Oncology, Dept. of Internal Medicine, Teikyo University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 12, 2021
Summary
Immune checkpoint inhibitors (ICIs) combined with chemotherapy significantly improve survival for extensive-stage small cell lung cancer. These combination therapies demonstrate good tolerability, with adverse event rates similar to chemotherapy alone.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Immune checkpoint inhibitors (ICIs) are a key cancer treatment strategy, improving overall survival in various carcinomas.
- Clinical trials validate ICIs as a crucial component in cancer therapy, including monotherapy, combination therapy, and chemotherapy combinations.
Purpose of the Study:
- To provide an overview of clinical trials investigating anti-PD-L1 antibodies combined with chemotherapy for extensive-stage small cell lung cancer.
- To discuss clinical questions and treatment recommendations based on recent trial data.
Main Methods:
- Review of two large phase III trials (IMpower133 and CASPIAN) evaluating atezolizumab and durvalumab with chemotherapy.
- Analysis of overall survival and treatment discontinuation rates due to adverse events.
Main Results:
- Combination therapy with anti-PD-L1 antibodies (atezolizumab, durvalumab) and chemotherapy demonstrated prolonged overall survival compared to chemotherapy alone in extensive-stage small cell lung cancer.
- Treatment discontinuation rates due to adverse events were comparable between combination therapy and chemotherapy alone groups, indicating good tolerability.
Conclusions:
- Anti-PD-L1 antibody plus chemotherapy is a recommended first-line treatment for extensive-stage small cell lung cancer in Japan.
- These combination therapies offer improved survival outcomes with manageable safety profiles.
Related Concept Videos
01:27Tumor Immunotherapy
801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
02:50Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K